Benzinga | Apr 30, 2021 10:27AM EDT

Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $92

Chardan Capital analyst Keay Nakae maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $112 to $92.